Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy

Autor: Egbert F. Smit, Maria Carmela Piccirillo, Francesco Perrone, Paolo Chiodini, Cesare Gridelli, Ciro Gallo, Dora Hatzidaki, Vittorio Gebbia, Wolfgang Schuette, Floris M Wachters, Nicola Lama, Massimo Di Maio, Vassilis Georgoulias, Elisabeth Quoix, Carlos Camps, Alessandro Morabito, Chun Ming Tsai, Koji Takeda
Přispěvatelé: DI MAIO, M, Lama, N, Morabito, A, Smit, Ef, Georgoulias, V, Takeda, K, Quoix, E, Hatzidaki, D, Wachters, Fm, Gebbia, V, Tsai, Cm, Camps, C, Schuette, W, Chiodini, Paolo, Piccirillo, Mc, Perrone, F, Gallo, Ciro, Gridelli, C., Pulmonary medicine, CCA - Innovative therapy
Jazyk: angličtina
Rok vydání: 2010
Předmět:
Oncology
Adult
Male
Cancer Research
medicine.medical_specialty
Multivariate analysis
Lung Neoplasms
WEEKLY DOCETAXEL
IRINOTECAN
COMBINATION CHEMOTHERAPY
Antineoplastic Agents
ERLOTINIB
Prognostic factors
NSCLC
THERAPY
Pooled analysis
PLUS GEMCITABINE
Internal medicine
Carcinoma
Non-Small-Cell Lung
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Stage (cooking)
Lung cancer
EVERY 3 WEEKS
Aged
Neoplasm Staging
Randomized Controlled Trials as Topic
Aged
80 and over
Performance status
Proportional hazards model
business.industry
Age Factors
Combination chemotherapy
PHASE-III TRIAL
Middle Aged
medicine.disease
Prognosis
Treatment Outcome
Meta-analysis
Prognostic score
COMPARING DOCETAXEL
Second-line treatment
Adenocarcinoma
Female
business
Epidemiologic Methods
Non-small-cell lung cancer
Zdroj: Di Maio, M, Lama, N, Morabito, A, Smit, E F, Georgoulias, V, Takeda, K, Quoix, E, Hatzidaki, D, Wachters, F M, Gebbia, V, Tsai, C M, Camps, C, Schuette, W, Chiodini, P, Piccirillo, M C, Perrone, F, Gallo, C & Gridelli, C 2010, ' Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials ', European Journal of Cancer, vol. 46, no. 4, pp. 735-743 . https://doi.org/10.1016/j.ejca.2009.12.013
European Journal of Cancer, 46(4), 735-743. Pergamon
European Journal of Cancer, 46(4), 735-743. ELSEVIER SCI LTD
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2009.12.013
Popis: Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 1197 patients (97%) had complete information. Median OS was 7.4 months. At multivariate analysis, prognosis was significantly influenced by gender (worse in males), performance status (PS), tumour histology (worse in squamous and other histology versus adenocarcinoma), stage (worse in IV versus IIIB), type of previous treatment (worse for patients pretreated with platinum) and response to first-line (worse for patients not obtaining objective response). Prognostic score values ranges from 0 to 14. When three categories were derived, median overall survival values were equal to 11.6, 7.5 and 3.0 months for best (9) category, respectively.Conclusion: Prognosis of patients eligible for second-line treatment of advanced NSCLC is significantly conditioned by gender, PS, histology, stage, previous use of platinum and response to first-line. A prognostic score was derived that discriminates well subjects with a relatively more favourable prognosis and those with very short life expectancy. (C) 2009 Elsevier Ltd. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: